APA (7th ed.) Citation

Alsakarneh, S., Al Ta'ani, O., Aburumman, R., Mikhail, I., Hashash, J. G., & Farraye, F. A. (2025). Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study. Alimentary Pharmacology & Therapeutics, 62(1), 72. https://doi.org/10.1111/apt.70139

Chicago Style (17th ed.) Citation

Alsakarneh, Saqr, Omar Al Ta'ani, Razan Aburumman, Inas Mikhail, Jana G. Hashash, and Francis A. Farraye. "Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study." Alimentary Pharmacology & Therapeutics 62, no. 1 (2025): 72. https://doi.org/10.1111/apt.70139.

MLA (9th ed.) Citation

Alsakarneh, Saqr, et al. "Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study." Alimentary Pharmacology & Therapeutics, vol. 62, no. 1, 2025, p. 72, https://doi.org/10.1111/apt.70139.